OpenAI has launched GPT-Rosalind, a new artificial intelligence model aimed at advancing research in biology, drug discovery, and translational medicine.
Named after pioneering scientist Rosalind Franklin, the model is built to process published evidence, data, tools, and experiments.
OpenAI is increasing its focus on health and medical research, developing advanced AI and collaborating with pharmaceutical firms. This is a critical area where AI is already transforming the identification of promising compounds and speeding up the journey from research to clinical application.
OpenAI states that advanced AI systems can help researchers navigate complex workflows more efficiently, explore more possibilities, uncover hidden connections, and develop better hypotheses faster.
The GPT-Rosalind model demonstrates superior performance in tasks requiring reasoning over molecules, proteins, genes, pathways, and disease biology. It also proves more effective in multi-step scientific workflows like literature review, sequence-to-function interpretation, experimental planning, and data analysis.
OpenAI plans to continuously enhance the model's biochemical reasoning capabilities for complex, tool-intensive scientific workflows, signaling a long-term commitment to AI for accelerating discoveries in critical societal areas like human health.
OpenAI is partnering with leading biotechnology and pharmaceutical companies, including Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific, to integrate GPT-Rosalind into their research and discovery processes.
Stéphane Bancel, CEO of Moderna, highlighted GPT-Rosalind's potential to help scientific teams reason across complex biological data and workflows, enabling quicker translation of insights into experimental plans and accelerating R&D.
This initiative follows OpenAI's recent partnership with Danish pharmaceutical company Novo Nordisk to expedite the delivery of new treatments. OpenAI CEO Sam Altman emphasized AI's role in reshaping industries and improving lives through life sciences advancements.